Allergan (AGN) Tops Q3 EPS by 10c; Issues Strong Q4, FY14 EPS Outlook

Allergan (NYSE: AGN) reported Q3 EPS of $1.78, $0.10 better than the analyst estimate of $1.68. Revenue for the quarter came in at $1.79 billion versus the consensus estimate of $1.78 billion.

Allergan sees FY2014 EPS of $6.27-$6.30, versus the consensus of $6.12. Allergan sees FY2014 revenue of $7.08-7.155 billion, versus the consensus of $7.15 billion.

Allergan sees Q3 2014 EPS of $1.80-$1.83, versus the consensus of $1.74. Allergan sees Q3 2014 revenue of $1.845-1.920 billion, versus the consensus of $1.87 billion.

For earnings history and earnings-related data on Allergan (AGN) click here.

You May Also Be Interested In

• Tesla touts acceleration of new models, but Q1 results fall short of estimates
• Range Resources (RRC) Tops Q1 EPS by 11c; offers production guidance
• Veralto Corporation (VLTO) Tops Q1 EPS by 6c, Offers Guidance